Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
Resource
Ann. Oncol., 26, 136-137
Journal
Ann. Oncol.
Journal Issue
26
Pages
136-137
Date Issued
2015
Date
2015
Author(s)
Wu, Y. -L.
Sequist, L. V.
Geater, S. L.
Orlov, S.
Lee, K. H.
Tsai, C. -M.
Kato, T.
Kiura, K.
Barrios, C. H.
Schuler, M.
Hirsh, V.
Yamamoto, N.
O'Byrne, K.
Mok, T.
Massey, D.
Maerten, A.
Yang, J. C. -H.